D
Duncan I. Jodrell
Researcher at University of Cambridge
Publications - 208
Citations - 14519
Duncan I. Jodrell is an academic researcher from University of Cambridge. The author has contributed to research in topics: Cancer & Pancreatic cancer. The author has an hindex of 55, co-authored 200 publications receiving 12597 citations. Previous affiliations of Duncan I. Jodrell include University of Maryland Marlene and Stewart Greenebaum Cancer Center & Edinburgh Cancer Research Centre.
Papers
More filters
Journal ArticleDOI
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.
Christine Feig,James O. Jones,Matthew Kraman,Richard J.B. Wells,Andrew Deonarine,Derek S. Chan,Claire M. Connell,Edward W. Roberts,Qi Zhao,Otavia L. Caballero,Sarah A. Teichmann,Tobias Janowitz,Duncan I. Jodrell,David A. Tuveson,Douglas T. Fearon +14 more
TL;DR: A single protein, CXCL12, from a single stromal cell type, the FAP+ CAF, may direct tumor immune evasion in a model of human PDA, which permitted the analysis of why immunotherapy is ineffective in this human disease.
Journal ArticleDOI
Capecitabine as Adjuvant Treatment for Stage III Colon Cancer
Chris Twelves,A. Wong,M. Nowacki,Markus Abt,Howard A. Burris,Alfredo Carrato,Jim Cassidy,Andrés Cervantes,Jan Fagerberg,Vassilis Georgoulias,Fares Husseini,Duncan I. Jodrell,P. Koralewski,Hendrik Kröning,Jean A. Maroun,Norbert Marschner,Joseph McKendrick,M. Pawlicki,Riccardo Rosso,Johannes Schüller,Jean-François Seitz,Borut Stabuc,Jerzy Tujakowski,Guy van Hazel,Jerzy Zaluski,Werner Scheithauer +25 more
TL;DR: Oral capecitabine is an effective alternative to intravenous fluorouracil plus leucovorin in the adjuvant treatment of colon cancer.
Journal ArticleDOI
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
Michael A. Jacobetz,Derek S. Chan,Albrecht Neesse,Tashinga E. Bapiro,Natalie Cook,Kristopher K. Frese,Christine Feig,Tomoaki Nakagawa,Meredith E. Caldwell,Heather I Zecchini,Martijn P. Lolkema,Ping Jiang,Anne Kultti,Curtis B. Thompson,Daniel C. Maneval,Duncan I. Jodrell,Gregory I. Frost,Harold Michael Shepard,Jeremy N. Skepper,David A. Tuveson +19 more
TL;DR: It is demonstrated that HA impedes the intratumoral vasculature in PDA and proposed that its enzymatic depletion be explored as a means to improve drug delivery and response in patients with pancreatic cancer.
Journal ArticleDOI
Inhibition of cancer cell growth by ruthenium(II) arene complexes
Morris Robert Edward,Rhona E. Aird,Piedad del Socorro Murdoch,Haimei Chen,Jeffrey Cummings,Nathan D. Hughes,Simon Parsons,Andrew Parkin,Gary Boyd,Duncan I. Jodrell,Peter J. Sadler +10 more
TL;DR: These chelated Ru(II) arene complexes have potential as novel metal-based anticancer agents with a mechanism of action different from that of the Ru(III) complex currently on clinical trial.
Journal ArticleDOI
In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer.
R E Aird,Jeffrey Cummings,A.A. Ritchie,M. Muir,Morris Robert Edward,Haimei Chen,Peter J. Sadler,Duncan I. Jodrell +7 more
TL;DR: High activity coupled to non cross-resistance in cisplatin resistant models merit further development of this novel group of anticancer compounds.